Sanofi Terminates Nurix’s SAR448272 Phase 1 Program
+1 new source since this summary was written
On Nov. 03, 2026, Sanofi told Nurix Therapeutics it would stop the Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix said it no longer expects development, regulatory or commercial milestones or royalties from SAR448272, while retaining eligibility for payments from other licensed programs. The company said its cash-runway guidance was unchanged, with operations funded into the second half of 2029.
Why it matters
The termination removes a potential future payment and royalty stream from Nurix’s partnered pipeline, although it does not change the company’s stated funding outlook. Jefferies responded by cutting its 12-month price target to $36 from $45 while keeping a Buy rating, according to the cited report.
Key facts
- 1Sanofi decided to discontinue the Phase 1 first-in-human trial of SAR448272 and terminate the program on Nov. 03, 2026. stocktitan.net
- 2Nurix does not expect future development, regulatory or commercial milestones or royalties tied to SAR448272, but remains eligible for payments from other licensed programs under the collaboration. stocktitan.net
- 3Nurix reported $1.1 billion in cash, cash equivalents and marketable securities to fund operations into the second half of 2029. finance.yahoo.com
- 4Jefferies lowered its 12-month price target for Nurix to $36 from $45 and retained a Buy rating. finance.yahoo.com
Open questions
- The reason for Sanofi’s termination is not established: one report linked it to nonclinical findings and attributed that claim to Leerink Partners analyst David Risinger, while another said Sanofi had not provided a detailed scientific explanation.
- The materials do not establish the amount of future SAR448272 milestones and royalties that Nurix would have received.
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.